In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDS Real-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practice Phase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDS Phase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis Program faculty: Courtney DiNardo, MD, MSCE Professor of Medicine Department of Leukemia MD Anderson Cancer Center Houston, Texas Brady L. Stein, MD, MHS Professor of Medicine Department of Hematology/Oncology Northwestern University Feinberg School of Medicine Chicago, Illinois Eunice S. Wang, MD Chief, Leukemia and Benign Hematology Service Professor of Oncology Roswell Park Comprehensive Cancer Center Buffalo, New York Resources: To download the slides associated with this podcast discussion, please visit the program page . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
